124 related articles for article (PubMed ID: 36735833)
1. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity
Kaneshige A; Bai L; Wang M; McEachern D; Meagher JL; Xu R; Kirchhoff PD; Wen B; Sun D; Stuckey JA; Wang S
J Med Chem; 2023 Feb; 66(4):2717-2743. PubMed ID: 36735833
[TBL] [Abstract][Full Text] [Related]
2. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.
Kaneshige A; Bai L; Wang M; McEachern D; Meagher JL; Xu R; Wang Y; Jiang W; Metwally H; Kirchhoff PD; Zhao L; Jiang H; Wang M; Wen B; Sun D; Stuckey JA; Wang S
Nat Chem Biol; 2023 Jun; 19(6):703-711. PubMed ID: 36732620
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
4. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
[TBL] [Abstract][Full Text] [Related]
5. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
Bai L; Zhou H; Xu R; Zhao Y; Chinnaswamy K; McEachern D; Chen J; Yang CY; Liu Z; Wang M; Liu L; Jiang H; Wen B; Kumar P; Meagher JL; Sun D; Stuckey JA; Wang S
Cancer Cell; 2019 Nov; 36(5):498-511.e17. PubMed ID: 31715132
[TBL] [Abstract][Full Text] [Related]
6. The STAT5b Linker Domain Mediates the Selectivity of Catechol Bisphosphates for STAT5b over STAT5a.
Gräb J; Berg A; Blechschmidt L; Klüver B; Rubner S; Fu DY; Meiler J; Gräber M; Berg T
ACS Chem Biol; 2019 Apr; 14(4):796-805. PubMed ID: 30835430
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
8. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
Wingelhofer B; Maurer B; Heyes EC; Cumaraswamy AA; Berger-Becvar A; de Araujo ED; Orlova A; Freund P; Ruge F; Park J; Tin G; Ahmar S; Lardeau CH; Sadovnik I; Bajusz D; Keserű GM; Grebien F; Kubicek S; Valent P; Gunning PT; Moriggl R
Leukemia; 2018 May; 32(5):1135-1146. PubMed ID: 29472718
[TBL] [Abstract][Full Text] [Related]
10. Stafiba: A STAT5-Selective Small-Molecule Inhibitor.
Eckhardt KS; Münzel T; Gräb J; Berg T
Chembiochem; 2023 Jan; 24(1):e202200553. PubMed ID: 36300584
[TBL] [Abstract][Full Text] [Related]
11. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
12. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
[TBL] [Abstract][Full Text] [Related]
13. Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
Li J; Tang B; Miao Y; Li G; Sun Z
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37830151
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL affects STAT5A and STAT5B differentially.
Schaller-Schönitz M; Barzan D; Williamson AJ; Griffiths JR; Dallmann I; Battmer K; Ganser A; Whetton AD; Scherr M; Eder M
PLoS One; 2014; 9(5):e97243. PubMed ID: 24836440
[TBL] [Abstract][Full Text] [Related]
17. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
18. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
19. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.
Verdier F; Rabionet R; Gouilleux F; Beisenherz-Huss C; Varlet P; Muller O; Mayeux P; Lacombe C; Gisselbrecht S; Chretien S
Mol Cell Biol; 1998 Oct; 18(10):5852-60. PubMed ID: 9742102
[TBL] [Abstract][Full Text] [Related]
20. Stafia-1: a STAT5a-Selective Inhibitor Developed via Docking-Based Screening of in Silico O-Phosphorylated Fragments.
Natarajan K; Müller-Klieser D; Rubner S; Berg T
Chemistry; 2020 Jan; 26(1):148-154. PubMed ID: 31503360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
